315 related articles for article (PubMed ID: 22001865)
41. Progressive Familial Intrahepatic Cholestasis.
Bull LN; Thompson RJ
Clin Liver Dis; 2018 Nov; 22(4):657-669. PubMed ID: 30266155
[TBL] [Abstract][Full Text] [Related]
42. Cenicriviroc, a cytokine receptor antagonist, potentiates all-trans retinoic acid in reducing liver injury in cholestatic rodents.
Yu D; Cai SY; Mennone A; Vig P; Boyer JL
Liver Int; 2018 Jun; 38(6):1128-1138. PubMed ID: 29356312
[TBL] [Abstract][Full Text] [Related]
43. Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates.
Shiri-Sverdlov R; Wouters K; van Gorp PJ; Gijbels MJ; Noel B; Buffat L; Staels B; Maeda N; van Bilsen M; Hofker MH
J Hepatol; 2006 Apr; 44(4):732-41. PubMed ID: 16466828
[TBL] [Abstract][Full Text] [Related]
44. Clinical and genetic study of ABCB4 gene-related cholestatic liver disease in China: children and adults.
Cao L; Ling X; Yan J; Feng D; Dong Y; Xu Z; Wang F; Zhu S; Gao Y; Cao Z; Zhang M
Orphanet J Rare Dis; 2024 Apr; 19(1):157. PubMed ID: 38610052
[TBL] [Abstract][Full Text] [Related]
45. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
[TBL] [Abstract][Full Text] [Related]
46. Expression Analysis of ATP-Binding Cassette Transporters ABCB11 and ABCB4 in Primary Sclerosing Cholangitis and Variety of Pediatric and Adult Cholestatic and Noncholestatic Liver Diseases.
Thoeni C; Waldherr R; Scheuerer J; Schmitteckert S; Roeth R; Niesler B; Cutz E; Flechtenmacher C; Goeppert B; Schirmacher P; Lasitschka F
Can J Gastroenterol Hepatol; 2019; 2019():1085717. PubMed ID: 31886153
[TBL] [Abstract][Full Text] [Related]
47. Importance of PPAR alpha for the effects of growth hormone on hepatic lipid and lipoprotein metabolism.
Ljungberg A; Lindén D; Améen C; Bergström G; Oscarsson J
Growth Horm IGF Res; 2007 Apr; 17(2):154-64. PubMed ID: 17307376
[TBL] [Abstract][Full Text] [Related]
48. Fenofibrate reverses liver fibrosis in cholestatic mice induced by alpha-naphthylisothiocyanate.
Lu Z; Li S; Luo J; Luo Y; Dai M; Zheng X; Qiu J; Yang J; Liu A
Pharmazie; 2021 Feb; 76(2):103-108. PubMed ID: 33714287
[TBL] [Abstract][Full Text] [Related]
49. [Childhood cholestasis and bile transporters].
Hierro L; Jara P
Gastroenterol Hepatol; 2005; 28(7):388-95. PubMed ID: 16137474
[TBL] [Abstract][Full Text] [Related]
50. Yinchenzhufu decoction protects against alpha-naphthylisothiocyanate-induced acute cholestatic liver injury in mice by ameliorating disordered bile acid homeostasis and inhibiting inflammatory responses.
Wang GF; Li YY; Shi R; Wang TM; Li YF; Li WK; Zheng M; Fan FB; Zou J; Zan B; Wu JS; Ma YM
J Ethnopharmacol; 2020 May; 254():112672. PubMed ID: 32084553
[TBL] [Abstract][Full Text] [Related]
51. ABCB4/MDR3 in health and disease - at the crossroads of biochemistry and medicine.
Prescher M; Kroll T; Schmitt L
Biol Chem; 2019 Sep; 400(10):1245-1259. PubMed ID: 30730833
[TBL] [Abstract][Full Text] [Related]
52. Simvastatin reduces atherogenesis and promotes the expression of hepatic genes associated with reverse cholesterol transport in apoE-knockout mice fed high-fat diet.
Song G; Liu J; Zhao Z; Yu Y; Tian H; Yao S; Li G; Qin S
Lipids Health Dis; 2011 Jan; 10():8. PubMed ID: 21241519
[TBL] [Abstract][Full Text] [Related]
53. A nontumorigenic variant of FGF19 treats cholestatic liver diseases.
Luo J; Ko B; Elliott M; Zhou M; Lindhout DA; Phung V; To C; Learned RM; Tian H; DePaoli AM; Ling L
Sci Transl Med; 2014 Jul; 6(247):247ra100. PubMed ID: 25080475
[TBL] [Abstract][Full Text] [Related]
54. Modeling hepatic osteodystrophy in Abcb4 deficient mice.
Hochrath K; Ehnert S; Ackert-Bicknell CL; Lau Y; Schmid A; Krawczyk M; Hengstler JG; Dunn J; Hiththetiya K; Rathkolb B; Micklich K; Hans W; Fuchs H; Gailus-Durner V; Wolf E; de Angelis MH; Dooley S; Paigen B; Wildemann B; Lammert F; Nüssler AK
Bone; 2013 Aug; 55(2):501-11. PubMed ID: 23545228
[TBL] [Abstract][Full Text] [Related]
55. Cytoprotection with ursodeoxycholic acid: effect in chronic non-cholestatic and chronic cholestatic liver disease.
Lirussi F; Okolicsanyi L
Ital J Gastroenterol; 1992 Jan; 24(1):31-5. PubMed ID: 1571577
[TBL] [Abstract][Full Text] [Related]
56. Fenofibrate prevents obesity and hypertriglyceridemia in low-density lipoprotein receptor-null mice.
Jeong S; Kim M; Han M; Lee H; Ahn J; Kim M; Song YH; Shin C; Nam KH; Kim TW; Oh GT; Yoon M
Metabolism; 2004 May; 53(5):607-13. PubMed ID: 15131765
[TBL] [Abstract][Full Text] [Related]
57. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases.
Trauner M; Fickert P; Halilbasic E; Moustafa T
Wien Med Wochenschr; 2008; 158(19-20):542-8. PubMed ID: 18998069
[TBL] [Abstract][Full Text] [Related]
58. Hydrophilic bile acids prevent liver damage caused by lack of biliary phospholipid in
Wang R; Sheps JA; Liu L; Han J; Chen PSK; Lamontagne J; Wilson PD; Welch I; Borchers CH; Ling V
J Lipid Res; 2019 Jan; 60(1):85-97. PubMed ID: 30416103
[TBL] [Abstract][Full Text] [Related]
59. Nordihydroguaiaretic acid improves metabolic dysregulation and aberrant hepatic lipid metabolism in mice by both PPARα-dependent and -independent pathways.
Zhang H; Shen WJ; Cortez Y; Kraemer FB; Azhar S
Am J Physiol Gastrointest Liver Physiol; 2013 Jan; 304(1):G72-86. PubMed ID: 23104557
[TBL] [Abstract][Full Text] [Related]
60. [Mechanism of Taurohyodeoxycholate-induced Biliary Phospholipid Efflux -Understanding the Function of the ABCB4 Enhancer for Developing Therapeutic Agents against Bile Salt-induced Liver Injury].
Ikeda Y
Yakugaku Zasshi; 2020; 140(11):1329-1334. PubMed ID: 33132268
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
